Pfizer Acquires Amplyx Pharmaceuticals

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

October 22, 2020

Pharmaceuticals

Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.

Alexion Pharmaceuticals Acquires Portola Pharmaceuticals

May 5, 2020

Biotechnology

Alexion Pharmaceuticals agreed to acquire Portola Pharmaceuticals in a cash tender offer at $18.00 per share to add Portola’s Factor Xa inhibitor reversal agent Andexxa and diversify Alexion’s commercial portfolio beyond its complement franchise. The transaction, unanimously approved by both boards, was expected to close in the third quarter of 2020 and will be funded with Alexion’s cash on hand.